Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis

Archives of Dermatology

Volumn 147, Issue 1, 2011, Pages 72-76

  Castela, Emeline ^a   Lebrun Frenay, Christine ^a   Laffon, Muriel ^a   Rocher, Fanny ^a   Cohen, Michael ^a   Leccia, Nathalie Cardot ^a   Bahadoran, Philippe ^a   Lacour, Jean Philippe ^a   Ortonne, Jean Paul ^a   Passeron, Thierry ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL PHOTOGRAPHY; MELANOCYTIC NEVUS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SKIN EXAMINATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DERMOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTEGRIN ALPHA4; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; MULTIPLE SCLEROSIS; NEVUS, PIGMENTED; PHOTOGRAPHY; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 78751542351     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.243     Document Type: Article

References (13)

1. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
2. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008;358(6):647-648.
3. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J Neurol. 2009;256(10):1771-1772.
4. Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med. 2008;359(1):99-100.
5. Kittler H, Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M. Frequency and characteristics of enlarging common melanocytic nevi. Arch Dermatol. 2000;136(3):316-320.
6. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol. 2000;43(3):467-476.
7. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008;14(3):399-405.
8. Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009;145(4):441-444.
9. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 1999;18(3):345-357.
10. Bauer R, Humphries M, Fässler R, Winklmeier A, Craig SE, Bosserhoff AK. Regulation of integrin activity by MIA. J Biol Chem. 2006;281(17):11669- 11677.
11. Garofalo A, Chirivi RG, Foglieni C, et al. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res. 1995;55(2):414-419.
12. Klemke M, Weschenfelder T, Konstandin MH, Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol. 2007;212(2):368-374.
13. Qian F, Vaux DL, Weissman IL. Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell. 1994;77(3):335-347.